Transport, metabolism, cytotoxicity and effects of novel taxanes on the cell cycle in MDA-MB-435 and NCI/ADR-RES cells
Language English Country Germany Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Antineoplastic Agents * metabolism pharmacokinetics pharmacology MeSH
- Cell Culture Techniques MeSH
- Cell Cycle drug effects MeSH
- Drug Resistance, Neoplasm drug effects MeSH
- Humans MeSH
- Drug Resistance, Multiple drug effects MeSH
- Molecular Structure MeSH
- Cell Line, Tumor MeSH
- Taxoids * metabolism pharmacokinetics pharmacology MeSH
- Cell Survival drug effects MeSH
- Chromatography, High Pressure Liquid MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Antineoplastic Agents * MeSH
- Taxoids * MeSH
Resistance of tumours to taxanes causes chemotherapy failure in numerous patients. Resistance is partly due to the low tumour uptake of taxanes and their rapid metabolism. Structural modifications of taxanes can reduce their P-glycoprotein-related efflux or decrease metabolism and consequently increase taxane efficiency. This study compared cytotoxicity and effects of the cell cycle, transport and metabolism of novel taxanes SB-T-1102, SB-T-1103, SB-T-1214 and SB-T-1216, fluorinated SB-T-12851, SB-T-12852, SB-T-12853, SB-T-12854 and IDN5109 with paclitaxel in paclitaxel-sensitive (MDA-MB-435) and paclitaxel-resistant (NCI/ADR-RES) human cancer cells. We have shown before that NCI/ADR-RES cells were 1,000-fold less sensitive to paclitaxel than MDA-MB-435 cells in correspondence to P-glycoprotein overexpression and up to 20-fold lower uptake of the drug in the resistant cells. The uptake of novel taxanes was 1.2 to 3.8 times lower than that of paclitaxel in the MDA-MB-435 cells, but 1.5 to 6.5 times higher in NCI/ADR-RES cells. NCI/ADR-RES cells were correspondingly only 2- to 6.6-fold less sensitive than the MDA-MB-435 cells to novel taxanes. Both cell lines showed minimal metabolism of the novel taxanes which was therefore not responsible for their different sensitivity, the observed differences in their individual efficiency and higher effects than paclitaxel. All novel taxanes caused G(2)/M block of the cell cycle similar to paclitaxel, but lower at concentrations by order of magnitude. Thus, structural modifications of taxanes resulting in their decreased P-glycoprotein-related transport probably caused their higher efficiency than paclitaxel in multidrug-resistant NCI/ADR-RES tumour cells.
See more in PubMed
Chem Rec. 2001;1(3):195-211 PubMed
Xenobiotica. 2006 Sep;36(9):772-92 PubMed
Annu Rev Med. 1997;48:353-74 PubMed
Biochemistry. 1981 May 26;20(11):3247-52 PubMed
J Chem Inf Model. 2009 Feb;49(2):424-36 PubMed
Oncogene. 2001 Aug 16;20(36):4995-5004 PubMed
Br J Cancer. 2000 Dec;83(12):1762-8 PubMed
ChemMedChem. 2007 Jul;2(7):920-42 PubMed
J Med Chem. 1996 Sep 27;39(20):3889-96 PubMed
Naunyn Schmiedebergs Arch Pharmacol. 2005 Jul;372(1):95-105 PubMed
Anticancer Res. 2009 Aug;29(8):2951-60 PubMed
Arch Toxicol. 2000 Oct;74(8):437-46 PubMed
Invest New Drugs. 2011 Jun;29(3):411-23 PubMed
Pharmacogenet Genomics. 2008 Mar;18(3):263-73 PubMed
J Chromatogr B Biomed Sci Appl. 2000 Oct 10;748(2):383-8 PubMed
Mol Pharmacol. 2003 Mar;63(3):766-72 PubMed
Semin Oncol. 2008 Apr;35(2 Suppl 2):S1-S14; quiz S39 PubMed
Crit Rev Oncol Hematol. 2001 Mar;37(3):237-47 PubMed
Cancer Chemother Biol Response Modif. 1997;17:59-79 PubMed
Naunyn Schmiedebergs Arch Pharmacol. 2003 Sep;368(3):200-9 PubMed
The Role of TRIP6, ABCC3 and CPS1 Expression in Resistance of Ovarian Cancer to Taxanes
